Effect of high dose vitamin D on blood glucose in critically ill patients

Comparing effect of high dose vitamin D and placebo on insulin resistance in critically ill patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014061218069N1

Enrollment

Registered

2014-10-06

Start date

2014-03-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia. Elevated blood glucose level

Interventions

Intervention 1: Single IM injection of 600000 IU vitamin D3 in intervention group (Two 300000 IU vitamin D3 ampules , each one contains 1 ml of drug). Intervention 2: IM injection of 2 placebo ampules

Treatment - Drugs

Placebo

Single IM injection of 600000 IU vitamin D3 in intervention group (Two 300000 IU vitamin D3 ampules , each one contains 1 ml of drug)

IM injection of 2 placebo ampules (each one contains 1 ml Placebo)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Critically ill patients aged between 18-65 years old with diagnosis of stress-induced hyperglycemia during the first 24 hours of intensive care unit (ICU) admission will be recruited. Exclusion criteria: Patients with following characteristics will be excluded: Diabetic patients, hemoglobin (Hbg) A1C>7.5, positive history of hypersensitivity to vitamin D or its analogues, hypercalcemia, any contraindication for intramuscular (IM) injection, current use of corticosteroids or any drugs affecting patients’ blood glucose.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma insulin. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.;Plasma glucose. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa Kit.;Serum level of 25 (OH) vitamin D3. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.;Adiponectin. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.	—

Measure

Time frame

Plasma insulin. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.;Plasma glucose. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa Kit.;Serum level of 25 (OH) vitamin D3. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.;Adiponectin. Timepoint: During 24 hours of ICU admission and 7 days after intervention. Method of measurement: Elisa kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNafiseh Sadat Alizadeh

Tehran University of Medical Sciences

nafisehalizadeh@yahoo.com+98 21 6695 4715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026